Key result
Adjuvanted MP-S177Q vaccination in mice improved viral neutralization and bronchoalveolar Th1-type cytokine responses following RSV challenge compared with MP-WT, unadjuvanted MP-S177Q, or vehicle.
Why the study?
Vaccines evaluated against RSV typically do not elicit complete or durable protective immunity.
Does MP-S177Q adjuvanted with MPLA improve immunogenicity and viral neutralization in BALB/c mice following RSV challenge?
Does MP-S177Q adjuvanted with MPLA improve immunogenicity and viral neutralization in BALB/c mice following RSV challenge?
A rationally mutated RSV G protein microparticle vaccine adjuvanted with MPLA improves viral neutralization and Th1-type cytokine responses in a mouse model, suggesting potential for advancing precision RSV vaccines.
Answers are grounded in this paper and cite their sources.
Animal data on NP-S177Q support further preclinical testing; leaves open durability versus approved F vaccines in humans.
Respiratory syncytial virus (RSV) is a significant cause of disease in the young and old. Recently, pre-fusion F protein vaccines for RSV have received food and drug administration (FDA) approval to protect adults aged 60 years and older; however, vaccines evaluated against RSV typically do not elicit complete or durable protective immunity. We previously showed that an RSV G protein central conserved domain (CCD) nanoparticle vaccine containing an S177Q mutation (NP-S177Q) induced favorable immunogenicity and RSV-neutralizing antibodies compared with RSV G protein vaccination alone in mice. Boosting BALB/c mice with NP-S177Q vaccines improved correlates of protection and reduced markers of immunopathology following RSV challenge. This study examined microparticle (MP) vaccines displaying the CCD with an RSV G S177Q mutation (MP-S177Q) adjuvanted with monophosphoryl lipid A (MPLA) in BALB/c mice. Our findings show that mice adjuvanted MP-S177Q vaccination develop effective viral neutralization compared with MP-WT and MP-S177Q vaccination and have improved bronchoalveolar Th1-type cytokine responses following the RSV challenge compared with MP-WT or vehicle-vaccinated mice. This study shows that a rationally mutated RSV G protein MP vaccine is safe, effective, and can advance precision RSV vaccines.
No takes yet. Share an insight, caveat, or question.
Bergeron et al. (2025) studied Respiratory syncytial virus (RSV). MP-S177Q vaccine adjuvanted with MPLA vs. MP-WT, unadjuvanted MP-S177Q, or vehicle was evaluated on Viral neutralization and bronchoalveolar Th1-type cytokine responses. Adjuvanted MP-S177Q vaccination in mice improved viral neutralization and bronchoalveolar Th1-type cytokine responses following RSV challenge compared with MP-WT, unadjuvanted MP-S177Q, or vehicle.
Synapse has enriched 10 related papers. Consider them for comparative context: